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An insight into the structural features ofhuman Waldenstr6m IgM proteins
which are responsible for theircapacity to bind and activate the first component
of complement (C) has been obtained. The basic approach has involved enzy-
matic and chemical fragmentation ofthe IgM molecule followedby examination
of the resulting fragments for C-fixing activity. A 6,800 mol wt fragment
obtained from the terminal C/,4 domain of a Waldenstr6m IgM molecule has
been shown to bind active C1 (C1) (1). This subfragment of IgM, which was
designated the C,,4 fragment, was found tobe composed ofthe CHc4 domain ofthe
Fcp, minus two tryptic peptides in the center of the loop. The first set of
experiments described in this communication were designed to evaluate the
dependence of C1-binding ability upon the presence of the intrachain disulfide
bond in the C,,4 fragment. In addition, the CH4 fragment before and after
reduction, as well as each of its component chains, were examined for their
ability to trigger the activation of the classical C pathway. Based upon these
studies we are able to present evidence suggesting that the C1-activating
function remains intact in these three fragments.
Materials and Methods
Preparation ofIgM and Its C4 Fragment.
￿
The methods used to isolate IgM and to obtain the
CH4 fragment have been previously reported (1, 2).
Isolation ofthe Two Peptide Chains Comprising the C4 Fragment. CH4fragments (5 mg/ml in
5 M guanidine-HCI adjusted to pH 7.5 by Tris base) were reduced by the addition of 2-mercapto-
ethanolto afinalconcentrationof0.1 M. After3 hof incubation at room temperature, a10%excess
of iodoacetamide was added and the pH was maintained at 7.5 by the addition of Tris base until
alkylation was complete. The reduction mixture was desalted by passage through a Bio-Gel P-2
column (Bio-Rad Laboratories, Richmond, Calif.) eluted with 1% NHQHCO3 and lyophilized.
Fractionationof the two peptides comprising the CH4 fragment was achieved by chromatography
through a column of Whatman DE-52 cellulose (H. Reeve Angel & Co., Inc., Clifton, N. J.)
equilibrated with 0.025 M NH,HC03, pH 8.0. After application of the sample, the column was
washed with one to two total column volof 0.025 M NH,HC03, pH 8.0, and a linear gradient (0.025
M NH,HCO3-1 M NH,HCO3) was begun. Pooled fractions from each of the two peaks eluted from
this column were lyophilized and redissolved in dextrose gelatin veronal buffer containing
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optimum amounts of Call and Mg++ (3).
C Assays.
￿
A description of the modified Cl-fixation assay has been previously reported (1) .
The ability to activate C1 was examined by incubating the fragments with normal humanserum
(NHS), followed by C4 titration. Titration of C4 was carried out by the procedure described by
Gaither et al. (4) using C4-deficient guinea pig serum (5).
Amino Acid Analyses .
￿
Acid hydrolysis was performed in 6 N HCl at 108°C for 20 h before
analysis on aDurrum aminoacid analyzer (Durrum Instrument Corp., Palo Alto, Calif.) using the
single column high pressure system.
Sequence Determination. The amino-terminal residues of each of the two disulfide-linked
peptides comprising the C4 fragment were first determined by the Edman-dansyl chloride
technique (6, 7). The intact C4fragment was sequenced automatically on a Beckman Model 890
sequencer (Beckman Instruments, Inc., Fullerton, Calif.). The identification of released phenyl-
thiohydantoin amino acids was performed by gas chromatography.
Results
The C,,4 fragment isolated from the Waldenstrom IgM, Dau, after limited
tryptic cleavage of the (Fc)Sp, fragment was found to consist of 24 residues on the
amino-terminal side of the Ct,4 domain linked by a disulfide bond to 32 residues
on the carboxyl side of the loop [i .e. according to the residue numbering of the
IgM, Ou, by Putnam et al. (8) the C H4 fragment consists of residues 468-491
joined to residues 515-546, with 23 residues having been cleaved out ofthe center
of the disulfide loop (1, 2)].
Separation of the two peptide chains comprising the C 4 fragment was
achieved by chromatography of the totally reduced sample through a DE-52
cellulose column . Amino acid compositional and sequence analysis of the first
major peak eluted by the NH,HCO, gradient indicated it consisted of the amino-
terminal chain of the Cp,4 domain (peptide A), while the second major peak was
found to consist of the carboxy-terminal chain of the disulfide loop (peptide B) .
The sequence of this region as published by Putnam et al. (8) for the IgM, Ou,
and by Watanabe et al. (9) for the IgM, Gal, has been given in Fig. 1 . In a
comparative study of the Fc sequence of three additional Waldenstrom IgM
proteins, including the Dau IgM used for the studies discussed herein, Florent et
al. (10) confirmed the sequence of residues 470-472, 515-517, and 519-526 for Dau
IgM and concluded that the Fc sequence is closely similar if not identical for
most and possibly all human pathological p-heavy chains . A spot check via
double sequencing in our automated sequenator of the intact Dau C,,4 fragment
confirmed the residues indicated by arrows in the sequence given in Fig. 1 .
The C1-fixing ability of the Dau C,i4 fragment before and after reduction, as
well as of each of its component chains (peptides A and B), was measured by the
C1-fixation assay. As seen in Fig. 2, there was a marked reduction in C1-binding
ability after cleavage of the disulfide bond. However, peptides A and B possessed
similar C1-fixing abilities, each being more efficient than the totally reduced
mixture of the two fragments . Table I presents the C1-fixation molar ratios
obtained from the data depicted in Fig. 2. If the number of micromoles of intact
C H4 fragment required to fix one-half of the available C1 is taken as 1, then
peptide B is 76 times less efficient, peptide A is 121 times less efficient, and the
reduced C 4 fragment (peptides A plus B) is 330 times less efficient than the
parent fragment.
We next examined the ability of the C,,4 fragment and of its respective
purified peptide chains to consume hemolytic C4 on incubation with fresh NHS.100
75
50
25
546
HZ N-GLU-SER-ALA-THR-ILE-THR-CYS- S-S- CYS-VAL-VAL-ALA-HIS-GLU-ALA-LEU-PRO-ASN-ARG-GOON
FIG. 1.
￿
The amino acid sequence of the C4 fragment as publishedby Putnam et al. (8) and
by Watanabe et al. (9) is given in this figure. The residues indicated by arrows are those
obtained by sequencing the Dau C4 fragment.
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Fixation of human Ci by Dau C,,4 fragments before and after reduction, and by
each of its respective purified peptide chains, designated peptides A and B. An amount ofC1
sufficient to produce 63% lysis of the cells in the absence of test material was used. After
incubation theamount ofunbound C1 wasdetermined and expressed as apercentage ofthat
found when no test material was added during the incubation.
As seen in Table 1, the results indicated that all three fragments were equiva-
lent in their ability to bringabout C4 consumption. The negative controls for the
C4-consumption assay were the 17 residue cyanogen bromide fragment which is
derived from the center of the C/14 domain (11) (i.e., the portion of the Cp,4
domain that is cleaved out to produce the CH4 fragment) and the pFc' fragment
(i .e ., Cy3 domain) of human IgG1 (12).
However, before concluding that C4 consumption is a reflection of C1 activa-
tion it is necessary to prove the following: (a) that the immunoglobulin frag-
ments are not activating a serum enzyme other than Cls which can in turn
consume C4, and (b) that the fragments are not directly interfering with C4 or
some other components of the test system . The first point was not examined
directly. However, since the fragments have been shown to bind isolated C1, it
seems probable that they, in fact, bind and activate C1 in NHS. In order to
determine if the C4 fragment could possibly be acting directly on C4 the
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TABLE I
Complement Fixation by Dau C  4 and its Fragments
Amount required to bind 50% of the available Ci .
t N.mol offragment required to fix 50% of the available Ci perpmol ofintact CH4 requiredto fix 50% ofthe Ci .
§ C4 site-forming units (SFU) consumed per Nmol of fragment divided by C4 SFU consumed per kmol ofintact
C4 .
fragments were incubated with functionally purified C4 (Cordis Laboratories,
Miami, Fla.) followed by a titration of the remaining C4 . When compared with
the control, which consisted of buffer plus C4, it was observed that no C4 had
been consumed by the CH4 fragment in the absence of C1 .
Discussion
The ability of the reduced Dau CH4 fragment and of its individual peptide
chains to fix C1 and to consume C4 in NHS has been examined . The fact that
cleavage of the disulfide bond in theCH4 fragment resulted in a decrease in the
efficiency of C1 fixation was not surprising . However, it was not expected that
peptideAand peptideB wouldfix C1 andconsume C4 in a similarmanner . Also
of interest was the fact that the individual A and B peptide chains were more
efficient at fixing C1 than the reduced mixture ofthe two chains . In analyzing
these results it is necessary to remember that the C1-fixation assay measures
the competition of immunoglobulin fragments with the EAC4 cells (sheep
erythrocytes [E] sensitized with rabbit antibody [A] to E to which C components
have been added) for the available C1, the final result depending on the relative
association constants . Perhaps when only one of the peptide chains is present
the binding is more avid than when a mixture of the two chains is involved .
However, C1 activation as manifested by C4 consumption occurs to a similar
degree with all threefragments. Moreover, the reduced C,,4 fragment appears to
consume C4 as effectively as each of its individual chains, and as effectively as
the intact CH4 fragment . This suggests that tight binding of C1 may not be a
prerequisite for activation as measured by C4 consumption . Transient binding
of C1 by the individual A and B peptide chains may therefore be sufficient to
activate C1, which in turn consumes C4 .
In conclusion, the observation that C1-activating and weak C1-fixing ability
can be associated with the completely reduced and alkylated peptides Aand B
indicates that although the intrachain disulfide bond may stabilize the tertiary
structure of the area in natural conditions, this bond is not absolutely essential
for the expression of these activities .
Summary
A 56 residue fragment derived from a Waldenstrom IgM protein and consist-
ing of 24 residues of the amino-terminal portion of the Ctt4 domain disulfide
Test material
Cl
Amount'
fixation
Molar ratio$
C4 consumption
Units C4 fixed per Nmol Molar ratio§
IHB
Dau C 4 1 .6 1 26,979 1 .0
Peptide B 56 76 34,019 1 .2
Peptide A 70 121 46,033 1 .7
Dan C4 reduced 400 330 26,266 1 .01326
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bonded to 32 residues of the carboxy-terminal region of the loop has been shown
to fix active C1 (C1) in a Cl-fixation assay . Cleavage of the disulfide bond within
the C,,4 fragment resulted in a marked decrease of Cl-fixing ability, although
the isolated A and B fragments did retain a limited ability to fix C1 .
Upon incubation with normal human serum the intact C4 fragment and
equal molar amounts of the isolated A and B peptides consumed C4 suggesting
that the Cl-activating determinant of IgM remains intact in these three frag-
ments . Furthermore, on a molar basis the intact or the reduced C4 fragment
consumed C4 as effectively as each of its component chains suggesting that
transient binding of C1 by the individual A and B peptide chains is sufficient to
activate C1 .
On the basis of these observations it is proposed that a classical complement
fixation function, i.e . C1 binding and activation, can be localized within a region
of the IgM molecule corresponding to the CA4 domain .
Received for publication 23 June 1975 .
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